Use of Serum Protein Measurements as Biomarkers that Can Predict the Outcome of Diabetic Foot Ulceration
Advances in Wound Care · 01.09.2024 · 13 (9) · 426-434
DOI: 10.1089/wound.2023.0126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Wound Care, erschienen am 01.09.2024. Verfasst von Georgios Theocharidis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Joslin-Beth Israel Deaconess Foot Center and The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Boston…. Hauptthemen laut MEDLINE: Diabetic Foot, Biomarkers, Wound Healing, Interleukin-10. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Objectives
To identify proteins that are prognostic for diabetic foot ulcer (DFU) healing and may serve as biomarkers for its management, serum samples were analyzed from diabetic mellitus (DM) patients. Approach: The serum specimens that were evaluated in this study were obtained from DM patients with DFU who participated in a prospective study and were seen biweekly until they healed their ulcer or the exit visit at 12 weeks. The group was divided into Healers (who healed their DFU during the study) and Non-Healers.
Results
Interleukin (IL)-10, IL-4, IL-5, IL-6, and IL-13 and interferon-gamma were higher in the Healers while Fractalkine, IL-8, and TNFα were higher in the Non-Healers. The trajectory of IL-10 levels remained stable over time within and across groups, resulting in a strong prognostic ability for the prospective DFU healing course. Classification and Regression Tree analysis created an 11-node decision tree with healing status as the categorical response. Innovation: Consecutive measurements of proteins associated with wound healing can identify biomarkers that can predict DFU healing over a 12-week period. IL-10 was the strongest candidate for prediction.
Conclusion
Measurement of serum proteins can serve as a successful strategy in guiding clinical management of DFU. The data also indicate likely superior performance of building a multiprotein biomarker score instead of relying on single biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Joslin-Beth Israel Deaconess Foot Center and The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pathology, Cancer Research Institute, HMS Initiative for RNA Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Mass General Brigham, Boston, Massachusetts, USA.
ORCID-Profile: Georgios Theocharidis, Aristidis Veves
Förderung
- NIDDK NIH HHS
Zitieren
APA
Theocharidis, G., Sumpio, B., Wang, E., Mezghani, I., Giurini, J. M., Kalavros, N., Valsami, E. A., Vlachos, I., Heydarpour, M., & Veves, A. (2024). Use of Serum Protein Measurements as Biomarkers that Can Predict the Outcome of Diabetic Foot Ulceration. Advances in Wound Care, 13(9), 426-434. https://doi.org/10.1089/wound.2023.0126
Vancouver
Theocharidis G, Sumpio B, Wang E, Mezghani I, Giurini JM, Kalavros N, et al. Use of Serum Protein Measurements as Biomarkers that Can Predict the Outcome of Diabetic Foot Ulceration. Advances in Wound Care. 2024;13(9):426-434. doi:10.1089/wound.2023.0126
BibTeX
@article{Theocharidis2024,
author = {Theocharidis, Georgios and Sumpio, Brandon and Wang, Enya and Mezghani, Ikram and Giurini, John M and Kalavros, Nikolaos and Valsami, Eleftheria-Angeliki and Vlachos, Ioannis and Heydarpour, Mahyar and Veves, Aristidis},
title = {Use of Serum Protein Measurements as Biomarkers that Can Predict the Outcome of Diabetic Foot Ulceration},
journal = {Advances in Wound Care},
year = {2024},
volume = {13},
number = {9},
pages = {426--434},
doi = {10.1089/wound.2023.0126}
}
EUVIMED